Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 46 EP applications Lachlan Clive Campbell has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11743481

2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF

IPC classification:
A61K 31/381, A61P 31/12, C07D 409/04, C07D 409/14, C07D 413/04, C07D 413/14, C07D 417/14, C07D 487/04, C07D 498/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11741554

BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS

IPC classification:
A61K 31/404, A61K 31/4184, C07D 215/36, C07D 235/18, C07D 263/57, C07D 401/04, C07D 401/12, C07D 403/04, C07D 405/04, C07D 413/12, C07D 471/04, C07D 513/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
The patent has been granted
EP11773361

VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS

IPC classification:
A61K 31/355, A61K 31/403, A61K 45/06, A61P 31/22
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12704135

NOVEL HETEROCYCLIC DERIVATIVES

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP12719083

GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES

IPC classification:
A61K 31/70, A61P 3/10, C07D 405/10
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP12748260

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/4245, A61P 3/00, A61P 25/28, C07D 271/06, C07D 413/10, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12770249

BENZOTHIAZOLONE COMPOUND

IPC classification:
A61K 31/428, A61P 21/00, C07D 277/68
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP12791856

NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/5375, A61P 25/00, C07D 265/30, C07D 413/04, C07D 413/12, C07D 413/14, C07D 417/12, C07D 471/04, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12798854

NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
C07D 473/16, C07D 519/00
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12805774

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

IPC classification:
A61K 31/4245, A61P 25/28, C07D 413/04, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP11711322

COMPOSITION COMPRISING THE AMYLOID BETA 1-6 PEPTIDE COUPLED TO A VIRUS-LIKE PARTICLE AND AN ADJUVANT

IPC classification:
A61K 39/00, A61K 47/48, A61P 25/28
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741412

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/4355, A61K 31/436, A61K 31/4365, A61K 31/437, A61K 31/4375, A61K 31/519, A61P 25/02, A61P 25/04, A61P 35/00, C07D 211/60, C07D 211/66, C07D 471/04, C07D 491/048, C07D 491/056, C07D 495/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741446

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/496, A61K 31/4985, A61K 31/551, A61P 25/02, A61P 25/04, A61P 35/00, C07D 241/04, C07D 243/08, C07D 403/04, C07D 413/04, C07D 413/06, C07D 487/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12772462

2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS

IPC classification:
A61K 31/5355, A61K 45/06, A61P 3/04, A61P 3/10, A61P 9/12, A61P 25/28, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13721227

TETRAHYDROPYRAN DGAT1 INHIBITORS

IPC classification:
A61K 31/422, A61K 31/4245, A61P 3/00, A61P 3/04, A61P 3/10, A61P 31/22, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13727385

CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS

IPC classification:
A61K 31/422, A61K 31/4245, A61P 3/00, A61P 3/04, A61P 3/10, C07D 413/12, C07D 417/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP13812075

SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST

IPC classification:
A61K 31/428, A61P 21/00, C07D 277/68
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
The patent has been granted
EP13792084

INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF

IPC classification:
A61K 31/403, A61P 31/06, C07D 209/42
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12708688

CRYSTALLINE OXAZINE DERIVATIVE AND ITS USE AS BACE INHIBITOR

IPC classification:
A61K 31/5377, A61K 45/06, A61P 25/00, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13826612

PYRIMIDO [4,5-B]QUINOLINE-4,5 (3H,10H)-DIONES AS NONSENSE MUTATION SUPPRESSORS

IPC classification:
A61K 31/513, A61P 7/00, A61P 21/00, A61P 35/00, A61P 43/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14164980

Gamma secretase inhibitors for treating respiratory diseases

IPC classification:
A61K 31/00, A61K 31/145, A61K 31/381, A61K 31/4164, A61K 31/4245, A61K 31/55, A61P 11/00, A61P 11/06
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14701273

MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS

IPC classification:
A61K 31/4439, A61P 3/04, A61P 3/10, C07D 413/12
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14704959

THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS

IPC classification:
A61K 31/433, A61K 31/454, A61K 31/496, A61P 21/00, C07D 417/10, C07D 417/12, C07D 417/14, C07D 487/04, C07D 487/10
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14708700

FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/428
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP15182564

ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS

IPC classification:
A61K 31/44, A61K 31/443, A61K 31/4436, A61K 31/4439, A61P 9/12, C07D 213/30, C07D 213/57, C07D 213/61, C07D 401/04, C07D 405/04, C07D 409/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12700390

NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

IPC classification:
A61K 31/5377, A61P 25/00, C07D 413/14, C07D 471/04, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11830236

SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS

IPC classification:
A61K 31/4025, A61K 31/403, A61K 31/437, A61K 31/4439, A61K 31/496, A61K 31/497, A61K 31/5377, A61K 31/7036, A61K 31/7056, A61K 31/7076, C07D 209/96, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 405/14, C07D 417/14, C07K 5/08
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14823688

HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE

IPC classification:
A61K 31/4375, A61K 31/472, A61K 31/522, A61P 25/02, C07D 217/26
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12160875

Heteroaryl derivatives as DGAT1 inhibitors

IPC classification:
A61K 31/426, A61K 31/427, A61K 31/454, A61K 31/4545, A61K 31/506, A61P 3/04, A61P 3/10, C07D 213/75, C07D 217/22, C07D 231/40, C07D 249/14, C07D 277/46, C07D 401/12, C07D 403/12, C07D 413/12, C07D 417/04, C07D 417/06, C07D 417/12, C07D 417/14, C07D 471/10
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15197854

2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS

IPC classification:
A61K 31/5355, A61P 3/04, A61P 3/10, A61P 9/12, A61P 25/28, C07D 413/14
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
PATENT GRANTED
EP12700194

BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS

IPC classification:
A61K 31/497, A61K 31/5375, A61K 31/5377, A61K 31/553, A61P 1/18
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14750931

1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS

IPC classification:
A61K 31/501, A61P 21/00, C07D 401/04, C07D 401/14, C07D 405/14, C07D 413/14, C07D 487/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11715244

FUROPYRIDINE COMPOUNDS AND USES THEREOF

IPC classification:
A61K 31/4355, A61K 31/541, A61P 31/14, A61P 35/00, C07D 491/048, C07D 491/147
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
No opposition filed within time limit
EP14806081

RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

IPC classification:
A61K 31/4353, A61K 31/437, A61K 31/4375, A61K 31/501, A61K 31/506, A61K 31/5377, A61K 31/5383, A61P 35/00, C07D 471/04, C07D 498/04, C07D 519/00
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14815965

MTOR INHIBITORS FOR ENHANCING THE IMMUNE RESPONSE

IPC classification:
A61K 31/436, A61K 31/4745, A61K 31/519, A61K 39/00, A61K 39/09, A61K 39/12, A61K 39/145, A61K 45/06, A61P 35/00, A61P 37/04
Applicant:
Novartis AG
Agent:
Holger Tostmann, Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Partnerschaft mbB
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP12705457

COMBINATIONS OF THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

IPC classification:
A61K 31/436, A61K 31/4745, A61K 31/496, A61K 31/52, A61K 31/5377, A61K 45/06, A61P 25/00
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12700232

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

IPC classification:
A61K 31/437, A61K 31/444, A61K 31/497, A61K 31/5377, A61P 25/00, C07D 413/12, C07D 471/04
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15727117

COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

IPC classification:
A61K 31/352, A61K 31/415, A61K 31/4245, A61K 31/44, A61K 31/506, A61P 19/02, C07D 491/18, C07D 493/08
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15774680

CARBOXAMIDE DERIVATIVES

IPC classification:
A61K 31/4192, A61P 9/12, A61P 19/02, A61P 19/04, A61P 19/08, C07D 403/12, C07D 487/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15725195

CARBOXAMIDE DERIVATIVES

IPC classification:
A61K 31/4155, A61K 31/422, A61P 9/12, A61P 11/00, A61P 19/02, A61P 19/08, C07D 413/12, C07D 413/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731119

PYRIDOPYRIMIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/38, A61K 31/505, C07D 471/04, C07D 495/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731121

NAPHTHYRIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/44, C07D 471/04, C07D 471/14, C07D 495/14
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15731120

PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

IPC classification:
A61K 31/519, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15823199

END CAPPED NUCLEIC ACID MOLECULES

IPC classification:
C07F 9/38, C07H 19/167, C07H 21/02
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
Request for examination was made
EP17171708

SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST

IPC classification:
A61K 31/428, A61P 21/00, C07D 277/68
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
The application has been published
EP16701560

SYNTHETIC APELIN FATTY ACID CONJUGATES WITH IMPROVED HALF-LIFE

IPC classification:
A61K 45/06, A61P 9/04, A61K 47/50
Applicant:
Novartis AG
Agent:
Lachlan Clive Campbell, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature